The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection
Open accessAbstract
BACKGROUND While an understanding of the epidemiology and clinical course of HIV-associated nephropathy (HIVAN) is growing, little is known about the risk factors and clinical course of the other renal diseases that may also occur as a complication of HIV infection. This study was undertaken to compare HIVAN to the spectrum of other kidney diseases seen among HIV-infected patients. METHODS This retrospective cohort study included all HIV-infected patients who underwent renal biopsy during the course of their clinical care at six major medical centers. Demographic and clinical information were abstracted from each patient's clinical record. Time to initiation of renal replacement therapy was compared for patients with lesions other than HIVAN to patients with HIVAN using Cox proportional hazards regression. RESULTS Eighty-nine patients (47 with lesions other than HIVAN and 42 with HIVAN) were available for inclusion. Patients with lesions other than HIVAN were less likely to be black (37/47 vs. 42/42, P= 0.02), more likely to have a positive hepatitis B surface antigen (10/37 vs. 4/42, P= 0.04), less likely to have the diagnosis of hypertension (24/46 vs. 31/42, P= 0.03), more likely to have a greater creatinine clearance at time of biopsy (60.6 vs. 39.0 cc/min, P= 0.008), and have a greater CD4 lymphocyte count at time of biopsy (287 vs. 187 cells/mL, P= 0.04) compared to patients with HIVAN. Lesions other than HIVAN were associated with a longer time to initiation of renal replacement therapy compared with HIVAN (HR 0.33, 95% CI 0.15-0.71, P= 0.005). Other factors associated with a longer time to renal replacement therapy included higher creatinine clearance at time of biopsy, greater CD4(+) lymphocyte count, the absence of hepatitis C antibody, and the use of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker. The type of renal disease (HIVAN vs. other) interacted significantly with HIV-1 RNA level and the use of antiretroviral therapy (P= 0.0001 and 0.006, respectively). Among patients with lesions other than HIVAN, the presence of nondetectable HIV-1 RNA was not associated with a greater risk of progression of renal disease (HR 0.27, P= 0.24). Among patients with HIVAN, because all patients had detectable virus at the time of institution of renal replacement therapy, this highly significant association could not be quantified. Among patients with lesions other than HIVAN, the use of antiretroviral therapy was not associated with the progression to renal replacement therapy (HR 3.29, P= 0.06). Among patients with HIVAN, the use of antiretroviral therapy was associated with a slower progression to renal replacement therapy (HR 0.24, P= 0.03). CONCLUSION Among HIV-infected patients with renal disease other than HIVAN, viral suppression and the use of antiretroviral therapy are not associated with a beneficial effect on renal function; thus, additional therapeutic strategies may need to be utilized. Because renal histology is associated with prognostic differences, these data provide outcomes information that will improve the clinical utility of renal biopsy among HIV-infected patients with renal disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Report of the committee on the genetic constitution of autosomes other than chromosomes 1, 2, and 6
Ruddle, F. H., & Meera Khan, P. (1976) · Cytogenetic and Genome Research · doi:10.1159/000130554 · Cited by 845
The Types of Renal Disease in the Acquired Immunodeficiency Syndrome
Rao, T. K. S., Friedman, E. A., & Nicastri, A. D. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704233161705 · Cited by 317
Marras, D., Bruggeman, L. A., Gao, F., Tanji, N., Mansukhani, M. M., Cara, A., Ross, M. D., Gusella, G. L., Benson, G., D'Agati, V. D., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-522 · Cited by 303
Self-citationHakim, R. M., & Lazarus, J. M. (1995) · Journal of the American Society of Nephrology · doi:10.1681/asn.v651319 · Cited by 271
Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression.
Bruggeman, L. A., Dikman, S., Meng, C., Quaggin, S. E., Coffman, T. M., & Klotman, P. E. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119525 · Cited by 247
Self-citationPredictors of proteinuria and renal failure among women with HIV infection
Szczech, L. A., Gange, S. J., van der Horst, C., Bartlett, J. A., Young, M., Cohen, M. H., Anastos, K., Klassen, P. S., & Svetkey, L. P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00094.x · Cited by 241
Self-citationHIV-1 induces renal epithelial dedifferentiation in a transgenic model of HIV-associated nephropathy
Barisoni, L., Bruggeman, L. A., Mundel, P., D'agati, V. D., & Klotman, P. E. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00152.x · Cited by 175
Self-citationHIV-associated immune-mediated renal disease
Kimmel, P. L., Phillips, T. M., Ferreira-Centeno, A., Farkas-Szallasi, T., Abraham, A., & Garrett, C. T. (1993) · Kidney International · doi:10.1038/ki.1993.386 · Cited by 148
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Levey, A. S., Atkins, R., Coresh, J., Cohen, E. P., Collins, A. J., Eckardt, K.-U., Nahas, M. E., Jaber, B. L., Jadoul, M., Levin, A., et al. (2007) · Kidney International · doi:10.1038/sj.ki.5002343 · Cited by 1,516
Mocroft, A., Kirk, O., Reiss, P., De Wit, S., Sedlacek, D., Beniowski, M., Gatell, J., Phillips, A. N., Ledergerber, B., & Lundgren, J. D. (2010) · AIDS · doi:10.1097/qad.0b013e328339fe53 · Cited by 406
Lucas, G. M., Ross, M. J., Stock, P. G., Shlipak, M. G., Wyatt, C. M., Gupta, S. K., Atta, M. G., Wools-Kaloustian, K. K., Pham, P. A., Bruggeman, L. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu617 · Cited by 310
Self-citationThe role of HIV in serious diseases other than AIDS.
Phillips, A. N., Neaton, J., & Lundgren, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3283174636 · Cited by 269
Metadata
- Authors
- Szczech, L. A., Gupta, S. K., Habash, R., Guasch, A., Kalayjian, R., Appel, R., Fields, T. A., Svetkey, L. P., Flanagan, K. H., Klotman, P. E., & Winston, J. A.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 66
- Issue
- 3
- Pages
- 1145-1152
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2047162910
- Cited by
- 340
- References
- 12
- FWCI
- 9.80
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. https://app.cochat.ai/papers/10.1111/j.1523-1755.2004.00865.x
- The paper
- Szczech, L. A., Gupta, S. K., Habash, R., Guasch, A., Kalayjian, R., Appel, R., Fields, T. A., Svetkey, L. P., Flanagan, K. H., Klotman, P. E., & Winston, J. A. (2004). The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. Kidney International. https://doi.org/10.1111/j.1523-1755.2004.00865.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.